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The publication of a randomized controlled trial in the vascular
arena is rare. The publication of a trial with negative results is rarer.
Han and colleagues should be applauded for an honest portrayal of
the use of alfimeprase in the setting of acute limb ischemia (ALI).
Alfimeprase, a novel recombinant variant of fibrolase, displayed prom-
ising results in preclinical and pilot studies. In contrast to available
thrombolytic agents, alfimeprase is a direct fibrinolytic enzyme and
has no effect on plasminogen. In addition, any drug that escapes into
the general circulation is quickly degraded by 2-macroglobulin
which is ubiquitous in plasma. These properties have the potential to
overcome limitations that exist with current therapies: the duration of
therapy and the risk of bleeding. A rapidly-acting, direct fibrinolytic
without systemic plasminogen activation and plasma neutralization
seem like ideal characteristics for a thrombolytic agent. In this report,
data from two essentially blinded, placebo-controlled, randomized
controlled trials evaluating alfimeprase for ALI are reported. Alas,
alfimeprase showed no greater effectiveness than placebo in ALI
patients withmostly femoral/popliteal thrombus in native arteries. In
fact, the rates of distal embolization and amputation in the treatment
groups were troubling.
Trial design is a critical component in the analyses of anyopen vascular surgery at 30 days” may not be a realistic endpoint in
patients with ALI. Thrombolysis may be the only therapy required
for patients with an embolus in an otherwise normal arterial tree.
However, most patients reported in these trials developed ALI
from thrombosis in the setting of extensive atherosclerotic occlu-
sive disease. The dissolution of thrombus uncovers a culprit lesion
which may require a limited surgical procedure for durable pa-
tency. Time to patency, cost, resource utilization, and grading of
the extent of open surgery are surrogate endpoints that can be used
for ALI trials and would likely favor alfimeprase in future studies.
Amputation-free survival is perhaps the best global endpoint, but
one that requires a large sample size. The inclusion of a placebo
group is difficult since acceptable results are obtained with throm-
bolysis in patients that are often ill-prepared to withstand major
limb revascularization. In fact, the surprising “effectiveness” of
intrathrombus placebo leads to the alternative conclusion that
percutaneousmechanical thrombectomy devices utilizing rheolysis
may be clinically beneficial in most cases of ALI. The compelling
preclinical data on alfimeprase did not translate into clinical effi-
cacy. Enhanced dosing and delivery strategies may salvage alfime-
prase. I agree with the authors that further study is warranted.
